Nitto Published Bispecific siRNA Research in Molecular Therapy Nucleic Acids, Establishing a Novel Approach for Simultaneous Silencing of Dual Disease Targets
Mol Ther Nucleic Acids . 2025 Nov 10; 36 (4): 102768
Nitto’s publication in Molecular Therapy Nucleic Acids highlights a groundbreaking approach to simultaneously suppress two key transcriptional regulators in the Hippo pathway—YAP and TAZ—using a single bispecific siRNA.
This work demonstrates potent knockdown across multiple species, synergistic inhibition of downstream signaling, and favorable in vivo efficacy—providing a novel therapeutic approach for liver diseases driven by YAP/TAZ activation, especially in nucleic acid therapeutics to address “undruggable” targets.
Featured in BioXconomy
This research was also highlighted by BioXconomy in an article discussing how bispecific siRNAs may enable simultaneous modulation of multiple disease drivers and open new opportunities for treating complex genetic diseases.
The article emphasizes the potential of Nitto’s bispecific siRNA platform to address targets that have been difficult to drug with conventional modalities.
Read more
https://www.bioxconomy.com/modalities/dual-targeting-sirnas-could-treat-complex-genetic-diseases
